Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heavy metal containing doai
Reexamination Certificate
2002-10-01
2004-02-03
Carr, Deborah D. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heavy metal containing doai
C554S075000
Reexamination Certificate
active
06686392
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a method to treat various conditions resulting from zinc deficiency and preparation of the same. In particular, the invention relates to the administration of novel zinc-in-oil or lipidic zinc reaction products for the treatment of benign prostatic hypertrophy.
BACKGROUND OF THE INVENTION
While zinc has heretofore been referred to as a trace element in human nutrition, in reality its concentration in humans is second only to that of iron in the metals. Zinc concentration in a prostate gland is much higher than in other human tissues.
Benign prostatic hypertrophy (BPH) is a common disorder of elderly men, affecting about 80% of men by the age of 80. It is a common histologic condition which conveys its morbidity through lower urinary tract symptoms and complications, such as acute urinary retention, obstructive uropathy, and urinary tract infections. Until recently, therapeutic options were limited, and transurethral surgery was the most common remedy.
Although zinc concentration in a prostate is usually high, it is reduced in pathological conditions, such as BPH. Available water-soluble zinc compounds when administered to a subject have minimal action upon lesions in therapeutic need of zinc because they are not taken up effectively by free lipids in the abnormal cells. Because of limited clinical results in reduction of prostate volume, zinc has remained unproven as an effective therapy in this condition. Thus, improved formulation and treatment methods are needed.
SUMMARY OF THE INVENTION
The present invention now addresses this problem by providing new formulations and treatment methods for administering zinc to a subject. It has now been discovered in the present invention that zinc can be administered by way of a simple formulation where zinc is incorporated into a lipid by bonding zinc to the non-polar part of the lipid. It has also been found that lipid-incorporated zinc is much more active biologically than non-lipidic formulations that contain zinc.
The present invention thus relates to novel compositions of lipids which include zinc incorporated therein. There compositions zinc-in-oil or lipidic zinc reaction products that are made by adding a zinc compound to a lipid component and heating the lipid component to a temperature of at least about 260° C. for a sufficient time to incorporate a predetermined amount of zinc into the lipid. As least about 0.1% zinc by weight can be incorporated, although between 1 and 10% zinc by weight are preferred.
The compositions of the invention may be administered to a patient who has cells or tissues that are deficient in zinc. One particular treatment, for example, is the administration of the compositions of the invention to a subject experiencing symptoms of BPH. The incorporated lipidic zinc is taken up preferentially by free lipids in abnormal cells or tissues, thus providing an effective treatment of BPH or other pathological conditions involving zinc deficiency.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
In general, abnormal cells and tissues in the body have free lipids. Thus, the invention is based on the recognition that a lipid or compound having a lipidic character introduced into the body can be selectively taken up by these abnormal cells.
Zinc intervenes in the body's action against pathological conditions. In these cases, zinc is mobilized from different parts of the body in the form of lipidic compounds, and these lipidic-zinc compounds are taken up specifically by lesions through abnormal free lipids contained in the lesions. Insufficient intervention of zinc in the body's defense against such lesions is due to the insufficient lipidic action of currently available zinc formulations. Accordingly, zinc compound having lipidic properties have been found to be useful as a therapeutic agent for patients who have zinc deficient pathological conditions such as BPH.
Zinc can be incorporated in the molecule of a fatty acid by heating together an organic or inorganic salt of zinc with a lipid. Preferably, the lipid is previously oxidized by being heated and mixed with air or oxygen. The mixtures of zinc and lipids are heated at a temperature of at least about 260° C. for a time until an exothermic reaction is observed, which reaction indicates the incorporation is taking place.
Examples of the zinc/lipid compositions that can be used according to the invention include the reaction products of allylic unsaturated lipids and a zinc compound. These reaction products are produced by heating a liquid composition containing a lipid, structurally characterized by allylic unsaturation with a zinc salt. Any zinc salt may be used in the invention, preferably, the zinc salt is an organic zinc salt such as zinc acetate or zinc carbonate. The liquid is preferably oxidized for example, by bubbling air or oxygen through the reaction mixture.
The allylic unsaturated compound is preferably a naturally occurring oil containing polyunsaturated fatty esters, such as an animal, vegetable, or fish oil, and particularly, polyunsaturated vegetable oils. Safflower oil, a vegetable oil, is the most advantageous oil for use in the present compositions in the practice of this invention.
The composition utilized should contain a significant percentage of molecular species having allylic moieties to render the compositions useful according to the invention. Such moieties are indicated by the following partial structures —CH═CH—CH
2
—CH═CH— and/or —CH═CH—CH═CH—CH
2
—. As indicated, the unsaturation can be conjugated or nonconjugated, but the composition must contain allylic methylene hydrogens.
Such compositions may initially be oxidized or heated in the presence of air or oxygen at the temperature range between about 100° C. and about 150° C. The oxygen can be obtained by merely heating the composition in a vessel which is open to the atmosphere, but preferably and advantageously, the source of oxygen is a gas such as air which is introduced into the oil with agitation, during the heating step. Oxygen or air can be injected into the heated oil as the introduction of air provides a source of agitation. Additional mixing or agitation can also be provided.
The heating step is conducted for a period of from about 15 minutes to about two hours. The temperature should be maintained at an upper limit within the range of about 260° C. to 280° C., and preferably about 265° C. to 270° C. These temperature limitations are based on a heating time of about one-half hour. The temperatures can be altered within limits depending on the time of heating. For example, when the temperature is about 265° C., the time is about one-half hour, while temperatures as high as 270° C. require a shorter period of time for heating. Higher temperatures for a prolonged period of time tend to degrade the composition and should thus be avoided.
Agitation, by stirring for example, aids in the reaction, and experiments to date indicate that a fairly violent stirring is advantageous. The introduction of air into the mixture during the heating is also very advantageous, particularly when the mixture is not subject to prolonged heating and thus, is the preferred method. The mixing or stirring can be accomplished with the introduction of the air.
After the reaction has taken place, the mixture is cooled. The remaining fluid is ready for use after appropriate sterilization for injection or incorporated into capsules, such as gelatin, for oral administration.
The precise nature of the compositions which result from the above-described treatment or the identity of the effective component or components is not presently known. It is known, however, that these compositions do include zinc. Although any amount above 0.1% of zinc incorporated into the composition is useful, a proportion of zinc in the range of about 1 to 10 weight percent has been found to be preferred. As mentioned above, although any zinc salt may be used, but an organic salt of zinc, such as zinc carbonate or zinc acetate, is preferred, w
Carr Deborah D.
Winston & Strawn LLP
LandOfFree
Lipidic zinc compounds and use for treatment of prostatic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipidic zinc compounds and use for treatment of prostatic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipidic zinc compounds and use for treatment of prostatic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3355294